Core Insights - Amplia Therapeutics Limited presented compelling preclinical data on its lead drug narmafotinib at the AACR Special Conference, highlighting its potential to enhance the efficacy of kRAS inhibitors in cancer treatment [2][3]. Company Overview - Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer [6]. - The company’s lead drug, narmafotinib, is a highly potent and selective FAK inhibitor that has shown promising results in preclinical studies [7]. Clinical Data - Preclinical data indicates that narmafotinib enhances the activity of kRAS inhibitors by blocking resistance pathways, thereby improving treatment efficacy and durability [3]. - Narmafotinib is currently involved in the ACCENT clinical trial, which has achieved a confirmed response rate of 35%, surpassing the 23% benchmark from the MPACT study for gemcitabine and Abraxane alone [8]. - An interim median progression-free survival (PFS) of 7.7 months has been reported in the ACCENT trial [8]. Industry Context - The kRAS inhibitors represent a new class of drugs in development for treating various cancers, with over 50 different kRAS inhibitors currently undergoing clinical studies globally [4]. - Despite the promising mid-stage clinical data for kRAS inhibitors, significant side effects and treatment-emergent resistance are common challenges faced in this area [4].